Literature DB >> 25024096

The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis.

R B Mueller1, M Schiff, T Kaegi, A Finckh, S R Haile, H Schulze-Koops, J von Kempis.   

Abstract

New American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria for the classification of rheumatoid arthritis (RA) have recently been proposed. The aim of this cohort study was to examine whether fulfilling these 2010 ACR/EULAR criteria at the first visit has an impact on the clinical course and on the radiographic progression of the disease. For this observational cohort study, we included patients from the Swiss RA registry SCQM with early RA or undifferentiated arthritis (UA, disease duration ≤1 year), as defined by the treating rheumatologist, who had not received any previous disease modifying anti-rheumatic drugs (DMARDs). Patients were categorized into two groups depending on whether or not they fulfilled the 2010 ACR/EULAR criteria (≥6 points vs <6 points) at the first visit. The primary outcome measures were the evolution of the DAS 28 and of radiographic erosions as measured by the Ratingen score over time. Of the 592 patients fulfilling the inclusion criteria, 352 satisfied the 2010 ACR/EULAR criteria at baseline, whereas 240 were not classifiable as definite RA. The ACR/EULAR criteria scores correlated with disease activity at disease onset (R (2) = 0.31). DMARD treatment was subsequently initiated in all patients, mostly with methotrexate (MTX). There were no significant differences in the therapeutic strategies between patients fulfilling or not fulfilling the classification criteria. Six months after inclusion, patients fulfilling the ACR/EULAR criteria developed a 39.1 % reduction of DAS 28 scores, as compared to a 33.6 % reduction in patients not fulfilling the ACR/EULAR criteria (p = 0.0002), independently of their respective treatment strategy. Importantly, the DAS 28 scores were higher in those patients fulfilling the ACR/EULAR criteria (ACR/EULAR positive patients) throughout the observation, as compared to patients not fulfilling those (ACR/EULAR negative patients). Average radiographic progression was higher among ACR/EULAR positive than negative patients (progression of Ratingen score/year 0.50 vs 0.32, resp., p = 0.03) after 3 years of follow-up. Among early RA/UA patients, a score of the 2010 ACR/EULAR criteria sufficient to classify RA selects patients with worse clinical outcome and more radiographic progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25024096     DOI: 10.1007/s10067-014-2737-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  25 in total

1.  Application of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis in Korean patients with undifferentiated arthritis.

Authors:  S J Jung; Y Kang; Y J Ha; K H Lee; S W Lee; S-K Lee; Y-B Park
Journal:  Scand J Rheumatol       Date:  2012-03-09       Impact factor: 3.641

2.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

3.  Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

Authors:  Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans
Journal:  Arthritis Rheum       Date:  2005-11

4.  The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study.

Authors:  Naomi B Klarenbeek; Melek Güler-Yüksel; Sjoerd M van der Kooij; K Huub Han; H Karel Ronday; Pit J S M Kerstens; Patrick E H Seys; Tom W J Huizinga; Ben A C Dijkmans; Cornelia F Allaart
Journal:  Ann Rheum Dis       Date:  2011-03-17       Impact factor: 19.103

5.  Toward a data-driven evaluation of the 2010 American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis: is it sensible to look at levels of rheumatoid factor?

Authors:  M P M van der Linden; M R Batstra; L E Bakker-Jonges; J Detert; H Bastian; H U Scherer; R E M Toes; G-R Burmester; M D Mjaavatten; T K Kvien; T W J Huizinga; A H M van der Helm-van Mil
Journal:  Arthritis Rheum       Date:  2011-05

6.  Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in Rheumatoid Arthritis.

Authors:  E Uitz; J Fransen; T Langenegger; G Stucki
Journal:  Rheumatology (Oxford)       Date:  2000-05       Impact factor: 7.580

7.  Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study.

Authors:  C Egsmose; B Lund; G Borg; H Pettersson; E Berg; U Brodin; L Trang
Journal:  J Rheumatol       Date:  1995-12       Impact factor: 4.666

8.  Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial.

Authors:  Henrike van Dongen; Jill van Aken; Leroy R Lard; Karen Visser; H Karel Ronday; Harry M J Hulsmans; Irene Speyer; Marie-Louise Westedt; André J Peeters; Cornelia F Allaart; René E M Toes; Ferdinand C Breedveld; Tom W J Huizinga
Journal:  Arthritis Rheum       Date:  2007-05

9.  The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial.

Authors:  A van der Heide; J W Jacobs; J W Bijlsma; A H Heurkens; C van Booma-Frankfort; M J van der Veen; H C Haanen; D M Hofman; G A van Albada-Kuipers; E J ter Borg; H L Brus; H J Dinant; A A Kruize; Y Schenk
Journal:  Ann Intern Med       Date:  1996-04-15       Impact factor: 25.391

10.  Diagnostic performance of the ACR/EULAR 2010 criteria for rheumatoid arthritis and two diagnostic algorithms in an early arthritis clinic (REACH).

Authors:  Celina Alves; Jolanda Jacoba Luime; Derkjen van Zeben; Anne-Margriet Huisman; Angelique Elisabeth Adriana Maria Weel; Pieternella Johanna Barendregt; Johanna Maria Wilhelmina Hazes
Journal:  Ann Rheum Dis       Date:  2011-05-27       Impact factor: 19.103

View more
  4 in total

1.  The clinical phenotype of Graves' disease occurring as an isolated condition or in association with other autoimmune diseases.

Authors:  M Rotondi; C Virili; S Pinto; F Coperchini; L Croce; N Brusca; M Centanni; L Chiovato
Journal:  J Endocrinol Invest       Date:  2019-08-12       Impact factor: 4.256

2.  Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM).

Authors:  Ruediger B Mueller; Nazim Reshiti; Toni Kaegi; Axel Finckh; Sarah R Haile; Hendrik Schulze-Koops; Michael Schiff; Michael Spaeth; Johannes von Kempis
Journal:  Clin Rheumatol       Date:  2016-11-12       Impact factor: 2.980

Review 3.  Rheumatoid arthritis treatment: the earlier the better to prevent joint damage.

Authors:  Sara Monti; Carlomaurizio Montecucco; Serena Bugatti; Roberto Caporali
Journal:  RMD Open       Date:  2015-08-15

4.  Clinical and radiographic course of early undifferentiated arthritis under treatment is not dependent on the number of joints with erosions at diagnosis: results from the Swiss prospective observational cohort.

Authors:  Ruediger B Mueller; Toni Kaegi; Sarah R Haile; Hendrik Schulze-Koops; Michael Schiff; Johannes von Kempis
Journal:  RMD Open       Date:  2018-06-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.